Richard A. Md Miller Purchases 577,634 Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Stock

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) CEO Richard A. Md Miller acquired 577,634 shares of Corvus Pharmaceuticals stock in a transaction on Monday, May 6th. The shares were bought at an average price of $1.73 per share, for a total transaction of $999,306.82. Following the purchase, the chief executive officer now owns 577,634 shares of the company’s stock, valued at $999,306.82. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink.

Corvus Pharmaceuticals Price Performance

CRVS stock opened at $1.96 on Thursday. The firm has a market cap of $96.12 million, a price-to-earnings ratio of -3.77 and a beta of 1.05. Corvus Pharmaceuticals, Inc. has a 1-year low of $1.05 and a 1-year high of $4.19. The firm has a fifty day moving average price of $1.77 and a two-hundred day moving average price of $1.78.

Corvus Pharmaceuticals (NASDAQ:CRVS) last posted its quarterly earnings results on Tuesday, March 19th. The company reported ($0.14) EPS for the quarter, meeting the consensus estimate of ($0.14). As a group, analysts expect that Corvus Pharmaceuticals, Inc. will post -0.47 EPS for the current fiscal year.

Hedge Funds Weigh In On Corvus Pharmaceuticals

An institutional investor recently raised its position in Corvus Pharmaceuticals stock. Towerview LLC increased its stake in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) by 67.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 342,478 shares of the company’s stock after purchasing an additional 137,478 shares during the period. Corvus Pharmaceuticals accounts for 0.3% of Towerview LLC’s portfolio, making the stock its 18th largest position. Towerview LLC owned approximately 0.70% of Corvus Pharmaceuticals worth $500,000 as of its most recent filing with the Securities and Exchange Commission. 46.64% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Cantor Fitzgerald restated an “overweight” rating on shares of Corvus Pharmaceuticals in a research note on Monday, April 1st. Mizuho restated a “neutral” rating and issued a $3.50 target price on shares of Corvus Pharmaceuticals in a research note on Wednesday, March 27th. Finally, Oppenheimer lifted their price target on Corvus Pharmaceuticals from $7.00 to $8.00 and gave the stock an “outperform” rating in a research note on Tuesday.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.